Anti-Diabetes Drugs - Taiwan

Taiwan

In Taiwan, the Anti-Diabetes Drugs market is predicted to witness a significant increase in revenue, with projections indicating a figure of US$291.80m in 2025.
This growth is expected to continue steadily, with an annual growth rate (CAGR 2025-2029) of 6.77%, leading to a market volume of US$379.20m by 2029.
When compared to other countries worldwide, United States is anticipated to generate the highest revenue in this market, with an estimated figure of US$40,820.00m in 2025.
Taiwan's growing aging population and increasing prevalence of diabetes drive the demand for innovative anti-diabetes drugs in the market.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Taiwan has been experiencing steady growth in recent years.

Customer preferences: Taiwan has a high prevalence of diabetes, which has led to a growing demand for anti-diabetes drugs. Patients in Taiwan typically prefer oral medications over insulin injections, which has driven the growth of the oral anti-diabetes drugs market.

Trends in the market: The anti-diabetes drugs market in Taiwan has been dominated by big pharma companies, but there has been an increase in the number of local companies entering the market. This has led to increased competition and lower prices for consumers. Additionally, there has been a shift towards more personalized medicine, with the development of new drugs that target specific genetic markers.

Local special circumstances: Taiwan has a national health insurance system that covers the majority of the population, which has made anti-diabetes drugs more accessible and affordable. Additionally, there has been a growing awareness of the importance of preventive healthcare, which has led to an increase in the number of people seeking treatment for diabetes.

Underlying macroeconomic factors: Taiwan has a rapidly aging population, which has led to an increase in the number of people with chronic diseases such as diabetes. Additionally, the country has a high prevalence of obesity, which is a major risk factor for diabetes. The government has taken steps to address these issues, such as implementing a sugar tax and promoting healthy eating and exercise habits. These factors are expected to continue driving growth in the anti-diabetes drugs market in Taiwan.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.